Estimates of benefits and harms of prophylactic use of aspirin in the general population

Annals of Oncology

Volumn 26, Issue 1, 2015, Pages 47-57

  Cuzick, Jack ^a   Thorat, M A ^a   Bosetti, C ^b   Brown, P H ^c   Burn, J ^d   Cook, N R ^e   Ford, L G ^f   Jacobs, E J ^g   Jankowski, J A ^a,h   La Vecchia, C ^b,i   Law, M ^a   Meyskens, F ^j   Rothwell, P M ^k   Senn, H J ^l   Umar, A ^f  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF TEXAS   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

^g AMERICAN CANCER SOCIETY   (United States)

^h PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

ⁱ UNIVERSITY OF MILAN   (Italy)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF OXFORD   (United Kingdom)

^l Tumor Center ZeTuP   (Switzerland)

more..

Author keywords

Aspirin; Benefit harm; Cancer; Cardiovascular disease; Gastrointestinal bleeding; Prevention

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT;

ADENOCARCINOMA; AGE; ARTICLE; BLEEDING; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM CANCER; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; EXTRCACRANIAL BLEEDING; FOLLOW UP; GASTROINTESTINAL CARCINOMA; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; LOW DRUG DOSE; LUNG CANCER; MAJOR EXTRACRANIAL BLEEDING; MALIGNANT NEOPLASTIC DISEASE; OBSERVATIONAL STUDY; PANCREAS CANCER; PEPTIC ULCER; POPULATION; PROSTATE CANCER; SECONDARY PREVENTION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; SYSTEMATIC REVIEW; TREATMENT DURATION; CHEMICALLY INDUCED; FEMALE; MALE; MYOCARDIAL INFARCTION; NEOPLASMS; STROKE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MYOCARDIAL INFARCTION; NEOPLASMS; STROKE;

EID: 84922532328     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu225     Document Type: Article

References (52)

1. Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
2. Rothwell PM, Fowkes FG, Belch JF et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41.
3. Rothwell PM, Price JF, Fowkes FG et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379: 1602-1612.
4. Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-1750.
5. Rothwell PM, Wilson M, Price JF et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379: 1591-1601.
6. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012; 13: 518-527.
7. Bosetti C, Rosato V, Gallus S et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012; 23: 1403-1415.
8. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
9. USPSTF. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 146: 361-364.
10. USPSTF. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150: 396-404.
11. Pignone M, Earnshaw S, McDade C, Pletcher MJ. Effect of including cancer mortality on the cost-effectiveness of aspirin for primary prevention in men. J Gen Intern Med 2013; 28: 1483-1491.
12. Cuzick J, Otto F, Baron JA et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507.
13. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613.
14. Cook NR, Lee IM, Zhang SM et al. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013; 159: 77-85.
15. Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst 2012; 104: 1208-1217.
16. Chan AT, Manson JE, Feskanich D et al. Long-term aspirin use and mortality in women. Arch Intern Med 2007; 167: 562-572.
17. Cook NR, Lee IM, Gaziano JM et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55.
18. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011; 128: 2444-2452.
19. Cancer Research UK. CancerStats-Cancer Statistics for the UK. London: Cancer Research UK 2011. http://www.cancerresearchuk.org/cancer-info/cancerstats/(April 2011, date last accessed).
20. Law M, Wald N, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. Health Technol Assess 2003; 7: 1-94.
21. Yeh RW, Sidney S, Chandra M et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155-2165.
22. Roger VL, Go AS, Lloyd-Jones DM et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012; 125: 188-197.
23. Thorat MA, Cuzick J. Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population. (Manuscript submitted).
24. Chan AT, Giovannucci EL, Meyerhardt JA et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134: 21-28.
25. Ratnasinghe LD, Graubard BI, Kahle L et al. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res 2004; 24: 3177-3184.
26. Thun MJ, Namboodiri MM, Calle EE et al. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327.
27. Jacobs EJ, Connell CJ, Rodriguez C et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 2004; 96: 524-528.
28. Gann PH, Manson JE, Glynn RJ et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220-1224.
29. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009; 302: 649-658.
30. Holmes MD, Chen WY, Li L et al. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28: 1467-1472.
31. Burn J, Gerdes A-M, Macrae F et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087.
32. Burn J, Bishop DT, Mecklin JP et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359: 2567-2578.
33. Friis S, Sorensen HT, McLaughlin JK et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer 2003; 88: 684-688.
34. Baron JA, Cole BF, Sandler RS et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899.
35. Cole BF, Logan RF, Halabi S et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst 2009; 101: 256-266.
36. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129-135.
37. Mihaylova B, Emberson J, Blackwell L et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581-590.
38. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008; 117: 2875-2883.
39. Earnshaw SR, Scheiman J, Fendrick AM et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011; 171: 218-225.
40. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med 2006; 144: 326-336.
41. Mills EJ, Wu P, Alberton M et al. Low-dose aspirin and cancer mortality: a metaanalysis of randomized trials. Am J Med 2012; 125: 560-567.
42. Kaufman DW, Kelly JP, Wiholm BE et al. The risk of acute major upper gastrointestinal bleeding among users of aspirin and ibuprofen at various levels of alcohol consumption. Am J Gastroenterol 1999; 94: 3189-3196.
43. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
44. Papatheodoridis GV, Sougioultzis S, Archimandritis AJ. Effects of Helicobacter pylori and nonsteroidal anti-inflammatory drugs on peptic ulcer disease: a systematic review. Clin Gastroenterol Hepatol 2006; 4: 130-142.
45. Chan FK, Sung JJ, Chung SC et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979.
46. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13.
47. Parsonnet J, Harris RA, Hack HM, Owens DK. Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials. Lancet 1996; 348: 150-154.
48. Roderick P, Davies R, Raftery J et al. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model. Health Technol Assess 2003; 7: 1-86.
49. Lanas A, Wu P, Medin J, Mills EJ. Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis. Clin Gastroenterol Hepatol 2011; 9: 762-768 e766.
50. Jankowski J, Moayyedi P. Re: cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 2004; 96: 885-887; author reply 887.
51. Cai S, Garcia Rodriguez LA, Masso-Gonzalez EL, Hernandez-Diaz S. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther 2009; 30: 1039-1048.
52. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal antiinflammatory drugs: population based nested case-control analysis. BMJ 2005; 331: 1310-1316.